Related Experiment Video
Updated: Aug 10, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Women and heart disease
1Division of Medicine and Therapeutics, Leicester Royal Infirmary, UK.
Insights
Cardiovascular disease is a major cause of death in women, with estrogen potentially delaying its onset. Estrogen replacement therapy may offer primary prevention, but further trials are needed.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Women's Health
Background:
- Coronary heart disease (CHD) and vascular diseases cause about half of all female deaths.
- Despite similar pathophysiology (atherosclerosis, thrombosis) to men, clinical endpoints are delayed in women.
- Endogenous estrogens are hypothesized to delay vascular disease onset, with CHD rare in premenopausal women and increasing post-menopause.
Purpose of the Study:
- To explore the potential of estrogen-replacement therapy (ERT) for primary prevention of cardiovascular disease (CVD) in postmenopausal women.
- To review the known cardioprotective mechanisms of estrogens.
- To assess the effectiveness of secondary preventative measures in women compared to men.
Main Methods:
- Review of existing literature on estrogen's effects on CVD.
- Analysis of observational studies supporting ERT for primary prevention.
- Comparison of ERT benefits with standard secondary prevention therapies.
Main Results:
- Estrogens offer cardioprotective benefits, including improved plasma lipids, anti-platelet effects, preserved endothelium-mediated vasodilation, and antioxidant properties.
- Observational studies suggest ERT may retard CVD development.
- Standard secondary preventative measures (aspirin, beta-blockade, ACE inhibitors, statins) appear equally effective in women and men.
Conclusions:
- Estrogen replacement therapy is a potential strategy for primary cardiovascular disease prevention in postmenopausal women.
- While observational data is supportive, definitive results from prospective randomized controlled trials are pending.
- Physicians may underutilize evidence-based secondary prevention interventions in high-risk women.
Abstract:
Coronary heart disease and other vascular diseases account for approximately half of all deaths in women. Although the underlying pathophysiological processes (atherosclerosis and thrombosis) are similar, deaths and other clinical end-points are significantly delayed compared to men. The reason for this sex-related delay in the expression of vascular disease remains a matter of debate but may be largely attributable to the actions of endogenous oestrogens: coronary heart disease manifestations are extremely rare in premenopausal women but increase after the menopause. These observations have lead to speculation that oestrogen-replacement therapy might continue to retard the development of cardiovascular disease in the post-menopausal years (primary prevention). The cardioprotective benefits of oestrogens include a favourable impact on plasma lipids, anti-platelet effects, preservation of endothelium-mediated vasodilatation and antioxidant effects. Several observational studies support this thesis but the results of prospective randomised controlled trials are still awaited. Secondary preventative measures such as aspirin, beta-blockade, ACE inhibition and HMG-CoA reductase inhibitors seem to be equally effective for women as men. However, there remains evidence that physicians are less likely to use such interventions in women at high risk.
More Related Videos
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures
01:27Heart Failure I: Introduction